Long-Acting Injectable PrEP: Transforming HIV Prevention

Overview of Long-Acting Injectable PrEP Options

Pre-exposure prophylaxis (PrEP) has emerged as a cornerstone in the fight against HIV, particularly for high-risk populations. The introduction of long-acting injectable PrEP (LAI-PrEP) represents a significant advancement in HIV prevention strategies. Long-acting injectable formulations, such as cabotegravir (CAB-LA), allow for less frequent dosing compared to traditional oral PrEP, enhancing adherence and reducing the risk of HIV transmission (Southern African HIV Clinicians Society, 2025).

CAB-LA is administered as an intramuscular injection, typically every two months, which significantly simplifies the regimen for patients who may struggle with daily oral medication. Recent studies have shown that this form of PrEP can achieve high levels of viral suppression in at-risk populations, making it a viable option for individuals who prefer fewer drug administration reminders (Wu et al., 2025).

In addition to CAB-LA, other long-acting modalities are currently being explored. For instance, the dapivirine vaginal ring (DVR) and the promising subcutaneous injection of lenacapavir, which is being developed for bi-annual dosing, highlight the ongoing evolution in PrEP administration strategies (Southern African HIV Clinicians Society, 2025).

Benefits of Long-Acting Injectable PrEP for High-Risk Populations

The adoption of long-acting injectable PrEP offers several distinct advantages for high-risk populations, particularly among groups disproportionately affected by HIV, such as men who have sex with men (MSM), transgender individuals, and people engaged in sex work. One of the most significant benefits of LAI-PrEP is its potential to enhance adherence, as the need for daily dosing is eliminated. In a study conducted in Taiwan, a modeling approach demonstrated that a PrEP program covering 50% of high-risk MSM could lead to a substantial reduction in new HIV infections, emphasizing the importance of accessibility and adherence (Wu et al., 2025).

Moreover, LAI-PrEP can mitigate the stigma associated with oral PrEP. Many individuals may feel uncomfortable carrying daily medications or may fear being judged based on their need for HIV prevention. With LAI-PrEP, individuals can maintain their privacy and experience less frequent reminders of their HIV status, which can enhance their overall quality of life (Southern African HIV Clinicians Society, 2025).

Additionally, LAI-PrEP is beneficial for individuals who may have difficulty with adherence due to memory issues, mental health challenges, or chaotic lifestyles. The reduced frequency of dosing can help ensure consistent protection against HIV, ultimately contributing to lower transmission rates (Wu et al., 2025).

Key Considerations for Healthcare Providers in PrEP Administration

Healthcare providers play a critical role in the successful implementation of long-acting injectable PrEP. The guidelines recommend that providers assess the appropriateness of LAI-PrEP based on individual patient needs, preferences, and potential barriers to access. Training providers on the benefits and limitations of LAI-PrEP is essential to empower them to offer comprehensive counseling to patients (Southern African HIV Clinicians Society, 2025).

Providers should also be aware of the clinical implications of switching between different PrEP modalities. For instance, individuals who experience side effects from oral PrEP may benefit from transitioning to a long-acting injectable formulation. It is vital for providers to engage in shared decision-making, allowing patients to express their preferences and concerns regarding different forms of PrEP (Wu et al., 2025).

Monitoring and follow-up are also key components of effective PrEP administration. Providers should establish a follow-up schedule that accommodates the administration intervals of long-acting formulations, ensuring that patients receive timely injections and necessary health assessments, including regular HIV testing and STI screenings (Southern African HIV Clinicians Society, 2025).

Patient Preferences and Acceptance for Long-Acting PrEP

Understanding patient preferences is crucial for the successful uptake of long-acting injectable PrEP. A recent study highlighted that a significant proportion of patients expressed a strong willingness to try injectable LAI-PrEP, particularly due to perceived benefits such as ease of administration and reduced stigma (Southern African HIV Clinicians Society, 2025).

In a survey conducted among individuals living with HIV, it was found that many preferred injectables to oral medications, citing the convenience and reduced frequency of administration as major factors influencing their choice (Wu et al., 2025). The acceptance of LAI-PrEP was notably higher among individuals who had experience with injectable medications in other contexts, such as contraceptives or vaccinations, indicating that familiarity with injections can positively impact willingness to adopt this form of HIV prevention (Southern African HIV Clinicians Society, 2025).

The introduction of educational materials and community engagement initiatives may further enhance acceptance. Informational campaigns that address misconceptions about long-acting injectable formulations and highlight their advantages over daily oral regimens can foster a more supportive environment for individuals considering LAI-PrEP (Wu et al., 2025).

Addressing Barriers to Long-Acting PrEP Adoption and Use

Despite the promising advantages of long-acting injectable PrEP, several barriers remain that can hinder widespread adoption. One major concern is the cost associated with these newer formulations, which can limit accessibility, particularly in low-resource settings. Providers have indicated that cost is a significant barrier to prescribing LAI-PrEP, which underscores the need for health systems to prioritize funding for these essential preventive measures (Wu et al., 2025).

Additionally, logistical challenges related to the administration of injectable PrEP must be addressed. Ensuring that healthcare facilities are equipped to provide timely and consistent injections is necessary for maintaining patient trust and adherence. Furthermore, educational programs for both providers and patients can help alleviate concerns about potential side effects and the efficacy of LAI-PrEP (Southern African HIV Clinicians Society, 2025).

Outreach efforts targeting high-risk populations are also crucial for increasing the uptake of long-acting injectable PrEP. Tailored strategies to engage communities most affected by HIV can help to raise awareness and promote the benefits of injectable formulations (Wu et al., 2025).

Frequently Asked Questions (FAQs)

What is long-acting injectable PrEP?
Long-acting injectable PrEP is a form of HIV prevention that involves the administration of antiretroviral medications via injection, typically every one to three months, rather than taking a daily oral pill.

Who should consider long-acting injectable PrEP?
High-risk populations, such as men who have sex with men, individuals with HIV-positive partners, and those who engage in transactional sex, should consider LAI-PrEP as a preventive measure against HIV.

What are the benefits of long-acting injectable PrEP compared to oral PrEP?
The benefits include improved adherence due to less frequent dosing, reduced stigma associated with carrying oral medications, and potentially better overall health outcomes for individuals at risk of HIV.

Are there any side effects associated with long-acting injectable PrEP?
Like all medications, LAI-PrEP may have side effects, but they are generally manageable. Common concerns include injection site reactions and potential changes in mental health or mood.

How can healthcare providers support patients in using long-acting injectable PrEP?
Providers can offer comprehensive counseling, ensure easy access to injections, monitor patients regularly, and address any concerns or questions about the medication.

References

1. Southern African HIV Clinicians Society guideline on pre-exposure prophylaxis to prevent HIV. Retrieved from https://doi.org/10.4102/sajhivmed.v26i1.1713

2. A modeling study of pre-exposure prophylaxis to eliminate HIV in Taiwan by 2030. Retrieved from https://doi.org/10.1038/s43856-025-00833-7

3. Two phase 1 studies of safety, tolerability, and pharmacokinetics of an EFdA prodrug (BRII-732) in healthy adult participants. Retrieved from https://pubmed.ncbi.nlm.nih.gov/12135525/

4. Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV. Retrieved from https://doi.org/10.1007/s40121-025-01129-y

5. Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychotics. Retrieved from https://doi.org/10.1038/s44294-025-00077-9

6. Patient and provider preferences for long-acting TB preventive therapy. Retrieved from https://doi.org/10.5588/ijtldopen.24.0670

7. Postnatal prophylaxis among infants born to women living with HIV in England, 2018−2022

8. Outcomes following prenatal exposure to DTG‐containing antiretroviral therapy regimens: data from the DOLOMITE‐EPPICC study

9. HIV treatment cascade among pregnant women with pre‐conception diagnosis: 2017−2022

10. The experience of pregnancy in women living with HIV (WLWH) between 2000 and 2023: a single‐centre retrospective observational analysis

11. A multicentre observational study to determine the safety and effectiveness of dolutegravir (DTG) use during pregnancy: data from DOLOMITE‐NEAT ID Network study

12. Management of reported side effects to PrEP: high rates of retention on PrEP after switching to a different F/TDF generic brand

13. Analysis of occupational accidents involving exposure to biological fluids in a Portuguese peripheral hospital: implementation and efficacy of post‐exposure prophylaxis

14. Prevalence of HIV drug resistance in people newly diagnosed with HIV who have used pre‐exposure prophylaxis in Europe: the PrEPaRe study. Retrieved from https://doi.org/10.5588/ijtldopen.24.0667

15. PrEP cascade improvement through same‐day PrEP initiation

16. HIV‐1 prevalence and pre‐exposure prophylaxis uptake among key populations in high‐income economies (2017−2023): a systematic review and meta‐analysis of real‐world studies

17. Preparing for long‐acting PrEP delivery: provider preferences for the provision of long‐acting PrEP differ between MSM and heterosexual individuals in Europe. Retrieved from https://doi.org/10.5588/ijtldopen.24.0670

18. Intention to use long‐acting PrEP among 4960 heterosexual women and men in 20 European countries: results from the PROTECT survey

19. Low uptake of mpox and HPV vaccination among PrEP users in Switzerland

20. Management of reported side effects to PrEP: high rates of retention on PrEP after switching to a different F/TDF generic brand